Drug Trial Radar · NCT06537999
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
46
Planned (sponsor's estimate)
Start
Sep 17, 2024
Primary completion
Dec 2026
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Dianthus TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of Claseprubart (DNTH103) in participants with multifocal motor neuropathy (MMN).
Conditions
- Multifocal Motor Neuropathy
Interventions
ClaseprubartDrug
* Day 1: IV loading dose * Week 1 to Week 15: Claseprubart administered SC every 2 weeks
PlaceboDrug
* Day 1: IV infusion of placebo * Week 1 to Week 15: placebo administered SC every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)Time frame: Baseline to Week 17
Locations
41 sites in 15 countries. Site status is shown where the registry gives one.
Clinical Study Site
Scottsdale, Arizona
Clinical Study Site
Los Angeles, California
Clinical Study Site
Bradenton, Florida
Clinical Study Site
Tampa, Florida
Clinical Study Site
Honolulu, Hawaii
Clinical Study Site
Kansas City, Kansas
Clinical Study Site
Cincinnati, Ohio
Clinical Study Site
Columbus, Ohio
Clinical Study Site
Houston, Texas
Cinical Study Site
Toronto, Canada
Cinical Study Site
Beijing, China
Clinical Study Site
Beijing, China
Cinical Study Site
Shanghai, China
Clinical Study Site
Aarhus, Denmark
Clinical Study Site
Copenhagen, Denmark
Clinical Study Site
Marseille, France
Clinical Study Site
Paris, France
Clinical Study Site
Rome, Italy
Clinical Study Site
Kota Kinabalu, Malaysia
Cinical Study Site
Kuala Lumpur, Malaysia
Cinical Study Site
Kuala Lumpur, Malaysia
Cinical Study Site
Permatang Pauh, Malaysia
Cinical Study Site
Sarawak, Malaysia
Clinical Study Site
Amsterdam, Netherlands
Clinical Study Site
Utrecht, Netherlands
Clinical Study Site
Skopje, North Macedonia
Clinical Study Site
Bydgoszcz, Poland
Clinical Study Site
Katowice, Poland
Clinical Study Site
Krakow, Poland
Clinical Study Site
Krakow, Poland
Clinical Study Site
Belgrade, Serbia
Cinical Study Site
Daegu, South Korea
Cinical Study Site #2
Seoul, South Korea
Clinical Study Site
Seoul, South Korea
Cinical Study Site
Alicante, Spain
Clinical Study Site
Barcelona, Spain
Cinical Study Site
Barcelona, Spain
Cinical Study Site
Istanbul, Turkey (Türkiye)
Clinical Study Site
London, England, United Kingdom
Clinical Study Site
Oxford, England, United Kingdom
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.